SGHT trades 79.9% below Wall Street's consensus target of $9.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SGHT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Sight Sciences, Inc. (SGHT) has a Wall Street consensus price target of $9.50, based on estimates from 9 covering analysts. With the stock currently trading at $5.28, this represents a potential upside of +79.9%. The company has a market capitalization of $287M.
Analyst price targets range from a low of $8.00 to a high of $12.00, representing a 42% spread in expectations. The median target of $9.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, SGHT trades at a trailing P/E of -7.1x. Analysts expect EPS to grow -13.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
GKOSGlaukos Corporation | $7.6B | $130.68 | $151.25 | +15.7% | Buy | — | 24 |
ATRCAtriCure, Inc. | $1.5B | $28.80 | $51.33 | +78.2% | Buy | 768.0x | 19 |
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
MASIMasimo Corporation | $9.4B | $179.95 | $180.00 | +0.0% | Buy | 32.7x | 23 |
TNDMTandem Diabetes Care, Inc. | $1.0B | $15.30 | $31.40 | +105.2% | Buy | — | 39 |
ABTAbbott Laboratories | $153.7B | $88.38 | $127.46 | +44.2% | Buy | 16.1x | 41 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
SYKStryker Corporation | $117.9B | $307.80 | $387.46 | +25.9% | Buy | 20.5x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.29 | $82.90 | +83.0% | Buy | 13.5x | 44 |
Quick answers to the most common questions about buying SGHT stock.
The consensus Wall Street price target for SGHT is $9.5, representing 79.9% upside from the current price of $5.28. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SGHT has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $9.5 implies 79.9% upside from current levels.
SGHT's current price is $5.28 with a consensus target of $9.5 (79.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $12 for SGHT, while the most conservative target is $8. The consensus of $9.5 represents the median expectation. These targets typically reflect 12-month expectations.
SGHT is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SGHT stock forecast based on 9 Wall Street analysts shows a consensus price target of $9.5, with estimates ranging from $8 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on SGHT, with a "Buy" consensus rating and $9.5 price target (79.9% upside). 4 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SGHT analyst price targets range from $8 to $12, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $9.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.